Cargando…
COVID‐19: vaccine’s progress
Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209887/ https://www.ncbi.nlm.nih.gov/pubmed/33960659 http://dx.doi.org/10.1111/1751-7915.13818 |
_version_ | 1783709212407234560 |
---|---|
author | Brüssow, Harald |
author_facet | Brüssow, Harald |
author_sort | Brüssow, Harald |
collection | PubMed |
description | Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus‐vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts. |
format | Online Article Text |
id | pubmed-8209887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82098872021-06-21 COVID‐19: vaccine’s progress Brüssow, Harald Microb Biotechnol Lilliput Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus‐vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts. John Wiley and Sons Inc. 2021-05-07 /pmc/articles/PMC8209887/ /pubmed/33960659 http://dx.doi.org/10.1111/1751-7915.13818 Text en © 2021 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Lilliput Brüssow, Harald COVID‐19: vaccine’s progress |
title | COVID‐19: vaccine’s progress |
title_full | COVID‐19: vaccine’s progress |
title_fullStr | COVID‐19: vaccine’s progress |
title_full_unstemmed | COVID‐19: vaccine’s progress |
title_short | COVID‐19: vaccine’s progress |
title_sort | covid‐19: vaccine’s progress |
topic | Lilliput |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209887/ https://www.ncbi.nlm.nih.gov/pubmed/33960659 http://dx.doi.org/10.1111/1751-7915.13818 |
work_keys_str_mv | AT brussowharald covid19vaccinesprogress |